Eli Lilly plans at least $27 billion in new U.S. manufacturing investments
It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.
With $27B plan to build 4 new plants, Eli Lilly doubles down on US drug manufacturing
Over the last few years, as Eli Lilly has revealed a series of manufacturing investments—each one seemingly more lavish than the last—the company’s spree has begged the question: What will they do | At a press conference in Washington,
Eli Lilly to build 4 more manufacturing sites in US
Eli Lilly ( LLY) announced Wednesday that it is ramping up US manufacturing, adding four new sites to help increase the production of key drug ingredients. Three of the four sites will produce active pharmaceutical ingredients (APIs), which are key ingredients in drugs.
Lilly plans to invest $27 billion in new US plants as Trump threatens pharmaceutical tariffs
Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a Washington press conference on Wednesday, as it grapples with the threat of drug import duties from the Trump administration.
Lilly plans to build four new pharmaceutical manufacturing sites in the U.S.
Eli Lilly (LLY) and Company announced at plans to bolster its domestic medicine production across therapeutic areas by building four new
Eli Lilly announces $27 billion investment in U.S. drug manufacturing sites
Eli Lilly plans to spend $27 billion to build new drug manufacturing sites in the U.S., at a time when President Trump is seeking to press drugmakers to move stateside.
Pharmaceutical Technology27m
FDA approvals decline but drug innovation remains strong even among small sponsors
The US Food and Drug Administration (FDA) approved 126 innovator and biosimilar drugs in 2024, significantly lower than the ...
FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the ...
Eli Lilly is selling higher-dose vials of Zepbound at a lower price to boost weight loss drug access
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower ...
Pharmaceutical Technology3h
Eli Lilly pays $10m upfront for Organovo’s FXR agonist
Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...
FDA declares end to Wegovy and Ozempic shortage
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
Eli Lilly Cuts Price of Weight-Loss Drug Zepbound for Self-Pay Patients
Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new ...
FierceBiotech5h
Eli Lilly buys Organovo's FXR program for $10M, sending biotech's stock skyrocketing 244%
Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...
Hosted on MSN8m
Eli Lilly Plans to Spend $27 Billion on New U.S. Plants
Drugmaker Eli Lilly plans to build four new manufacturing plants in the U.S., a $27 billion investment that the company ...